Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted — page 2

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

98 documents · page 2 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-GHK-CU-MONOG/006Draft monograph: GHK-CuDr Constança Glendinning-UcheThe monograph should state what the compound costs
DRAFT-GHRP-2-MONOG/004Draft monograph: GHRP-2Dr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-GHRP-6-MONOG/001Draft monograph: GHRP-6Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-GLUTATHIONE-/001Draft monograph: GlutathioneDr Ludmila TollemacheThe monograph should state what the compound costs
DRAFT-GLUTATHIONE-/006Draft monograph: GlutathioneGeorgiana ZimmerthalThe document set should be published in translation
DRAFT-KISSPEPTIN-1/002Draft monograph: Kisspeptin-10Dr Constança Glendinning-UcheThe monograph should state what the compound costs
DRAFT-KISSPEPTIN-1/004Draft monograph: Kisspeptin-10Dr Liesbeth Nordhagen industryThe document should not describe uses outside the approved indication
DRAFT-KPV-MONOGRAP/001Draft monograph: KPVDr Leonhard QuennevilleThe document should state what a reader ought to do
DRAFT-KPV-MONOGRAP/008Draft monograph: KPVDr Georgiana MountstephenThe document set should be published in translation
DRAFT-KPV-MONOGRAP/015Draft monograph: KPVBertrand Ollerenshaw industryThe document should not describe uses outside the approved indication
DRAFT-LL-37-MONOGR/002Draft monograph: LL-37Dr Theodora IngelbrechtThe document should state what a reader ought to do
DRAFT-MELANOTAN-II/001Draft monograph: Melanotan-IIDr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-MOTS-C-MONOG/001Draft monograph: MOTS-cDr Wojciech Kaltenbach-MensahThe monograph should state what the compound costs
DRAFT-NAD-PLUS-MON/006Draft monograph: NAD+ (nicotinamide adenine dinucleotide)Dr Emiliana OllerenshawThe document set should be published in translation
DRAFT-PETRELINTIDE/001Draft monograph: PetrelintideDr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-PETRELINTIDE/002Draft monograph: PetrelintideDr Jerome PetrossianThe monograph should state what the compound costs
DRAFT-PRAMLINTIDE-/014Draft monograph: PramlintideDr Lorcan Whitmarsh-ObiThe document should state what a reader ought to do
DRAFT-PT-141-MONOG/012Draft monograph: PT-141 (bremelanotide)Dr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-SELANK-MONOG/001Draft monograph: SelankDr Rurik Haverkamp-DialloThe document set should be published in translation
DRAFT-SELANK-MONOG/003Draft monograph: SelankDr Ludmila TollemacheThe monograph should state what the compound costs
DRAFT-SEMAX-MONOGR/005Draft monograph: SemaxDr Henrike JastrzębskaThe document should state what a reader ought to do
DRAFT-SS-31-MONOGR/014Draft monograph: SS-31 (elamipretide)Dr Liesbeth Nordhagen industryThe document should not describe uses outside the approved indication
DRAFT-SURVODUTIDE-/008Draft monograph: SurvodutideDr Constança Glendinning-UcheThe monograph should state what the compound costs
DRAFT-TB-500-MONOG/001Draft monograph: TB-500Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-TB-500-MONOG/003Draft monograph: TB-500Dr Wolfram Quintanilha industryThe document should not describe uses outside the approved indication
DRAFT-TESAMORELIN-/001Draft monograph: TesamorelinDr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-TESAMORELIN-/012Draft monograph: TesamorelinDr Liesbeth Nordhagen industryThe document should not describe uses outside the approved indication
DRAFT-THYMALIN-MON/001Draft monograph: ThymalinDr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-THYMOSIN-ALP/003Draft monograph: Thymosin alpha-1Dr Theodora IngelbrechtThe document should state what a reader ought to do
DRAFT-THYMOSIN-ALP/007Draft monograph: Thymosin alpha-1Bertrand Ollerenshaw industryThe document should not describe uses outside the approved indication

page 2 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.